UBS/CALL/IDORSIA/2.405/0.2/21.03.25 Stock

UBS/CALL/IDORSIA/2.405/0.2/21.03.25 Share Price

Warrant

UPB5SU

CH1357483648

Market Closed - Bid/Ask 16:20:01 13/06/2024 BST			After market 16:15:00
0.21 ^CHF	-4.55%		0.21	-.--%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart IDORSIA LTD

Chart UBS/CALL/IDORSIA/2.405/0.2/21.03.25

Latest news about IDORSIA LTD

New semester, new state of mind	12:00pm
Idorsia Wins European Commission's Nod for Resistant Hypertension Treatment	09:06am	MT
Idorsia’s JERAYGO (aprocitentan) approved in Europe as first and only ERA for the treatment of resistant hypertension	06:00am	GL
Idorsia Ltd Receives Approval from the European Commission for JERAYGO?	06:00am	CI

More news

Static data

Product type	Plain-Vanilla-Warrants
Buy / Sell	CALL
Underlying	IDORSIA LTD
Issuer	UBS
	UPB5SU
ISIN	CH1357483648
Date issued	10/06/2024
Strike	2.405 CHF
Maturity	21/03/2025 (263 Days)
Parity	5 : 1
Emission price	0.24 CHF
Emission volume	N/A
Settlement	Physisch
Currency	CHF

Technical Indicators

Highest since issue	0.22 CHF
Lowest since issue	0.21 CHF
Spread	0.02 CHF
Spread %	9.09%

Company Profile

Idorsia Ltd is a Switzerland-based biopharmaceutical company, which specializes in the discovery and development of small molecules, to meet significant unmet medical needs. The Company will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The Company's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.

Sector

More about the company